|1.||Richelson, Elliott: 9 articles (06/2012 - 01/2003)|
|2.||Boules, Mona: 7 articles (06/2012 - 01/2003)|
|3.||Richelson, E: 7 articles (04/2012 - 02/2000)|
|4.||Boules, M: 4 articles (10/2009 - 02/2000)|
|5.||Williams, Katrina: 3 articles (06/2012 - 01/2010)|
|6.||Fauq, A: 3 articles (08/2001 - 02/2000)|
|7.||Smith, Kristin E: 2 articles (06/2012 - 10/2011)|
|8.||Fredrickson, Paul: 2 articles (10/2003 - 01/2003)|
|9.||Yerbury, Sally: 2 articles (10/2003 - 01/2003)|
|10.||McCormick, D J: 2 articles (05/2000 - 02/2000)|
|1.||Schizophrenia (Dementia Praecox)
09/14/2009 - "These results confirm that NT69L possesses antipsychotic-like activity and therefore could be beneficial in the treatment of schizophrenia."
02/11/2010 - "The modulatory role of NT69L on the dopaminergic and serotonergic neurotransmission systems both of which are implicated in the pathophysiology of schizophrenia is discussed."
02/11/2010 - "The persistent efficacy of NT69L with chronic treatment provides further support for the therapeutic use of neurotensin (NT) agonists to treat schizophrenia and possibly other disorders that are characterized by PPI deficits. "
01/22/2010 - "NT69L, an analog of neurotensin(8-13), acts like an atypical antipsychotic drug in several dopamine-based animal models used to study schizophrenia. "
01/22/2010 - "Thus, NT69L showed antipsychotic-like effects in this glutamate-based animal model for studying schizophrenia. "
12/01/2001 - "NT69L induced rapid and prolonged mild brain hypothermia after ACA in this rat model and reduced neurological deficits."
10/31/2011 - "The role of NTS2 in the development of tolerance to NT69L in mouse models for hypothermia and thermal analgesia."
06/22/2001 - "Acute injection of NT69L (0.19-6.1 micromol/kg, s.c./i.p.) caused hypothermia (>2.5 degrees C) and reduction in spontaneous locomotor activity but failed to induce catalepsy. "
02/21/2000 - "The ED(50) of NT69L for hypothermia was 390 microgram/kg. NT69L (up to 5 mg/kg i.p.) did not produce catalepsy. "
02/21/2000 - "Its blockade of climbing was very potent with an ED(50) (effective dose at 50% of maximum) of 16 microgram/kg. Both apomorphine and NT69L caused a long-lasting hypothermia, which was greater with the peptide but not synergistic in combination with apomorphine. "
|4.||Tobacco Use Disorder (Nicotine Dependence)
10/17/2003 - "The most widely studied and successful of these compounds, called NT69L, holds promise as a therapeutic agent for Parkinson's disease, schizophrenia, psychostimulant abuse and nicotine dependence, and serves as a tool to study the cellular and molecular effects of NT."
01/01/2003 - "The present study is the first report, to our knowledge, of a possible role for neurotensin in the development of nicotine dependence, and suggests that neurotensin analogs such as NT69L may be explored as treatment for nicotine and other psychostimulant abuse."
|5.||Parkinson Disease (Parkinson's Disease)
|8.||Cocaine (Cocaine HCl)
|9.||Glutamic Acid (Glutamate)
|10.||Morphine (MS Contin)